DMARDS and infections in rheumatoid arthritis

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Abstract: Patients with rheumatoid arthritis (RA) has an increased infections risk and morbidity and mortality related to infections. This increased risk may occur due to the disease itself with intrinsic cellular immunity alterations or as a results of drugs used to control the disease. The potential risk of infections related to conventional disease modifying anti-rheumatic drugs (DMARDs) is not completely clarified. Methotrexate (MTX) may increase the infectious risk, but its positive effect on disease activity results in a reduction of further risk factors for infections. Data about the increased risk of pneumonia or reactivation of silent infection remain controversial. Leflunomide (LEF) seems safe in controlled trial even if it has been associated with the onset of infections requiring hospitalization, such as pneumonia. Data about other DMARDs are scanty and the main cause of interruption of therapy is related to toxicity different from infection. Beside the general positive profile of DMARDs as for infectious risk, a careful use and tight control of the patients is recommended.

Original languageEnglish
Pages (from-to)139-143
Number of pages5
JournalAutoimmunity Reviews
Volume8
Issue number2
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Rheumatoid Arthritis
Antirheumatic Agents
Infection
leflunomide
Pneumonia
Methotrexate
Cellular Immunity
Hospitalization
Morbidity
Mortality
Pharmaceutical Preparations

Keywords

  • DMARDs
  • Infection
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

DMARDS and infections in rheumatoid arthritis. / Caporali, Roberto; Caprioli, Marta; Bobbio-Pallavicini, Francesca; Montecucco, Carlomaurizio.

In: Autoimmunity Reviews, Vol. 8, No. 2, 12.2008, p. 139-143.

Research output: Contribution to journalArticle

@article{60faadcd09c14d86be4a237cea5cf8d2,
title = "DMARDS and infections in rheumatoid arthritis",
abstract = "Abstract: Patients with rheumatoid arthritis (RA) has an increased infections risk and morbidity and mortality related to infections. This increased risk may occur due to the disease itself with intrinsic cellular immunity alterations or as a results of drugs used to control the disease. The potential risk of infections related to conventional disease modifying anti-rheumatic drugs (DMARDs) is not completely clarified. Methotrexate (MTX) may increase the infectious risk, but its positive effect on disease activity results in a reduction of further risk factors for infections. Data about the increased risk of pneumonia or reactivation of silent infection remain controversial. Leflunomide (LEF) seems safe in controlled trial even if it has been associated with the onset of infections requiring hospitalization, such as pneumonia. Data about other DMARDs are scanty and the main cause of interruption of therapy is related to toxicity different from infection. Beside the general positive profile of DMARDs as for infectious risk, a careful use and tight control of the patients is recommended.",
keywords = "DMARDs, Infection, Rheumatoid arthritis",
author = "Roberto Caporali and Marta Caprioli and Francesca Bobbio-Pallavicini and Carlomaurizio Montecucco",
year = "2008",
month = "12",
doi = "10.1016/j.autrev.2008.05.001",
language = "English",
volume = "8",
pages = "139--143",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - DMARDS and infections in rheumatoid arthritis

AU - Caporali, Roberto

AU - Caprioli, Marta

AU - Bobbio-Pallavicini, Francesca

AU - Montecucco, Carlomaurizio

PY - 2008/12

Y1 - 2008/12

N2 - Abstract: Patients with rheumatoid arthritis (RA) has an increased infections risk and morbidity and mortality related to infections. This increased risk may occur due to the disease itself with intrinsic cellular immunity alterations or as a results of drugs used to control the disease. The potential risk of infections related to conventional disease modifying anti-rheumatic drugs (DMARDs) is not completely clarified. Methotrexate (MTX) may increase the infectious risk, but its positive effect on disease activity results in a reduction of further risk factors for infections. Data about the increased risk of pneumonia or reactivation of silent infection remain controversial. Leflunomide (LEF) seems safe in controlled trial even if it has been associated with the onset of infections requiring hospitalization, such as pneumonia. Data about other DMARDs are scanty and the main cause of interruption of therapy is related to toxicity different from infection. Beside the general positive profile of DMARDs as for infectious risk, a careful use and tight control of the patients is recommended.

AB - Abstract: Patients with rheumatoid arthritis (RA) has an increased infections risk and morbidity and mortality related to infections. This increased risk may occur due to the disease itself with intrinsic cellular immunity alterations or as a results of drugs used to control the disease. The potential risk of infections related to conventional disease modifying anti-rheumatic drugs (DMARDs) is not completely clarified. Methotrexate (MTX) may increase the infectious risk, but its positive effect on disease activity results in a reduction of further risk factors for infections. Data about the increased risk of pneumonia or reactivation of silent infection remain controversial. Leflunomide (LEF) seems safe in controlled trial even if it has been associated with the onset of infections requiring hospitalization, such as pneumonia. Data about other DMARDs are scanty and the main cause of interruption of therapy is related to toxicity different from infection. Beside the general positive profile of DMARDs as for infectious risk, a careful use and tight control of the patients is recommended.

KW - DMARDs

KW - Infection

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=56349118190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349118190&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2008.05.001

DO - 10.1016/j.autrev.2008.05.001

M3 - Article

C2 - 19014871

AN - SCOPUS:56349118190

VL - 8

SP - 139

EP - 143

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 2

ER -